Eikon Therapeutics, Inc. (Nasdaq: EIKN) priced its upsized initial public offering (IPO) of 21,177,600 shares at USD 18.00 per share. The offering, yielded gross proceeds of approximately USD 381 million, adding to around USD 1.16 billion in previous venture capital funding. This reflects the investor confidence in Eikon’s “super-resolution” platform, as well as the ability of CEO Roger Perlmutter, formerly president of Merck Research Laboratories where he led Keytruda (pembrolizumab)’s development.

The Nobel-winning SMT platform

Eikon’s competitive edge is built on its proprietary Single Molecule Tracking (SMT) platform, derived from research into the application of super-resolved fluorescence microscopy to observe protein-protein interactions in living cells in real-time. Eikon co-founder Dr. Eric Betzig shared the 2014 Nobel Prize in Chemistry for his part in that research, carried out at the Howard Hughes Medical Institute.

Unlike traditional static assays, Eikon’s cellular SMT (cSMT) approach visualizes hundreds of thousands of protein motion events per second, coupling advanced engineering with AI to evaluate chemical perturbations at a scale suitable for high-throughput discovery. The platform can also be used to carry out genome-wide screens to pinpoint disease pathways previously inaccessible to conventional imaging tools. Clinical pipeline and licensing

The capital infusion from the IPO will support Eikon in advancing a pipeline of six publicly disclosed drug candidates, four of which have already reached the clinical stage. Eikon continues to leverage its SMT platform for internal discovery, but has also balanced its portfolio with several in-licensed assets.

  • EIK1001 (lead candidate): Currently in Phase II clinical trials, this dual TLR7/8 agonist is being evaluated for the treatment of melanoma and non-small cell lung cancer (NSCLC). The asset was in-licensed from Seven and Eight Biopharmaceuticals in 2023.
  • EIK1003 and EIK1004 (PARP1 program): Resulting from a 2023 agreement with China-based Impact Therapeutics, these next-generation PARP1-selective inhibitors are both in Phase I studies. EIK1003 targets general oncology indications, while EIK1004 is a specialized CNS-penetrant candidate.
  • EIK1005: An internally derived program targeting WRN helicase, currently in the early clinical phase for patients with microsatellite instability-high (MSI-H) tumors.
  • Early-Stage Research: The pipeline is further supported by an IND-enabling program (EIK1006) and multiple discovery-stage assets targeting protein homeostasis and DNA damage repair, bolstered by the acquisition of Cleave Therapeutics’ preclinical portfolio.